Literature DB >> 22994796

Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: confirmation in a prospective study.

Vassiliki Galea1, Amir Khaterchi, Francoise Robert, Grigoris Gerotziafas, Mohamed Hatmi, Ismail Elalamy.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a potentially lethal adverse effect of heparin therapy. Accurate and rapid HIT laboratory diagnosis when HIT is suspected is crucial. The combination of an immunological assay with a functional test improves the accuracy of HIT, but functional assays are currently limited to a few laboratories. Multiplate® analyzer (Dynabyte, Munich, Germany) is a practical, semi-automated and easy-to-perform platelet aggregation assay. The aim of this study is to explore whether heparin-induced platelet aggregation in whole blood assessed by Multiplate® (Heparin-induced multiple electrode aggregometry, HIMEA) can replace platelet aggregation test (PAT) in platelet-rich plasma. For this purpose, HIMEA performance in HIT diagnosis was prospectively evaluated. HIMEA and PAT were compared to serotonin-release assay (SRA) in 200 well-characterized consecutive patients suspected for HIT. HIMEA was found to be more sensitive (81% vs. 76%) and more specific (99% vs. 96%) than PAT compared to SRA. Both tests showed a high negative predictive value while HIMEA had a better positive predictive value. HIMEA has overall better performance characteristics than PAT for the detection of HIT platelet-activating antibodies. The combination of an immunological assay with HIMEA could be a feasible option in non-specialized laboratories for HIT diagnosis optimization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22994796     DOI: 10.3109/09537104.2012.724736

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  8 in total

1.  Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Authors:  Luise Goldmann; Rundan Duan; Thorsten Kragh; Georg Wittmann; Christian Weber; Reinhard Lorenz; Philipp von Hundelshausen; Michael Spannagl; Wolfgang Siess
Journal:  Blood Adv       Date:  2019-12-10

Review 2.  Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  H D Husseinzadeh; P A Gimotty; A M Pishko; M Buckley; T E Warkentin; A Cuker
Journal:  J Thromb Haemost       Date:  2017-05-11       Impact factor: 5.824

Review 3.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

4.  An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination.

Authors:  Ingvild Hausberg Sørvoll; Kjersti Daae Horvei; Siw Leiknes Ernstsen; Ingvild Jenssen Laegreid; Svetlana Lund; Renathe Henriksen Grønli; Magnus Kringstad Olsen; Hege Karine Jacobsen; Anna Eriksson; Anne Marie Halstensen; Eirik Tjønnfjord; Waleed Ghanima; Maria Therese Ahlen
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

Review 5.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

Review 6.  Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Authors:  Brigitte Tardy; Thomas Lecompte; François Mullier; Caroline Vayne; Claire Pouplard
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

7.  Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose.

Authors:  Katarzyna Krzywicka; Anita van de Munckhof; Julian Zimmermann; Felix J Bode; Giovanni Frisullo; Theodoros Karapanayiotides; Bernd Pötzsch; Mayte Sánchez van Kammen; Mirjam R Heldner; Marcel Arnold; Johanna A Kremer Hovinga; José M Ferro; Diana Aguiar de Sousa; Jonathan M Coutinho
Journal:  Blood       Date:  2022-04-28       Impact factor: 25.476

8.  Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford-AstraZeneca) Vaccination.

Authors:  Azhar Ali; Jeremy Rabouhans; Tooba Salar; Sakib Moghul; Sudhakaran Makkuni; Tom Browne; Rumman Ahmed; Imran Syed; Ali Zaman
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-18       Impact factor: 2.740

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.